Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. Engelman JA, et al. Among authors: lindeman n. Science. 2007 May 18;316(5827):1039-43. doi: 10.1126/science.1141478. Epub 2007 Apr 26. Science. 2007. PMID: 17463250
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. Paez JG, et al. Among authors: lindeman n. Science. 2004 Jun 4;304(5676):1497-500. doi: 10.1126/science.1099314. Epub 2004 Apr 29. Science. 2004. PMID: 15118125
Copy number variants and pharmacogenomics.
Ouahchi K, Lindeman N, Lee C. Ouahchi K, et al. Among authors: lindeman n. Pharmacogenomics. 2006 Jan;7(1):25-9. doi: 10.2217/14622416.7.1.25. Pharmacogenomics. 2006. PMID: 16354122 Review.
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing.
Thomas RK, Nickerson E, Simons JF, Jänne PA, Tengs T, Yuza Y, Garraway LA, LaFramboise T, Lee JC, Shah K, O'Neill K, Sasaki H, Lindeman N, Wong KK, Borras AM, Gutmann EJ, Dragnev KH, DeBiasi R, Chen TH, Glatt KA, Greulich H, Desany B, Lubeski CK, Brockman W, Alvarez P, Hutchison SK, Leamon JH, Ronan MT, Turenchalk GS, Egholm M, Sellers WR, Rothberg JM, Meyerson M. Thomas RK, et al. Among authors: lindeman n. Nat Med. 2006 Jul;12(7):852-5. doi: 10.1038/nm1437. Epub 2006 Jun 25. Nat Med. 2006. PMID: 16799556
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Jackman DM, et al. Among authors: lindeman n. Clin Cancer Res. 2006 Jul 1;12(13):3908-14. doi: 10.1158/1078-0432.CCR-06-0462. Clin Cancer Res. 2006. PMID: 16818686
Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJ. Sequist LV, et al. Among authors: lindeman ni. Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4403s-4408s. doi: 10.1158/1078-0432.CCR-06-0099. Clin Cancer Res. 2006. PMID: 16857818 Review.
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
Jackman DM, Holmes AJ, Lindeman N, Wen PY, Kesari S, Borras AM, Bailey C, de Jong F, Jänne PA, Johnson BE. Jackman DM, et al. Among authors: lindeman n. J Clin Oncol. 2006 Sep 20;24(27):4517-20. doi: 10.1200/JCO.2006.06.6126. J Clin Oncol. 2006. PMID: 16983123 No abstract available.
212 results